MARKET

CPIX

CPIX

Cumberland
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.400
0.000
0.00%
Closed 19:29 03/03 EST
OPEN
3.400
PREV CLOSE
3.400
HIGH
3.488
LOW
3.350
VOLUME
49.97K
TURNOVER
--
52 WEEK HIGH
4.450
52 WEEK LOW
2.770
MARKET CAP
51.13M
P/E (TTM)
-8.9947
1D
5D
1M
3M
1Y
5Y
[Cumberland Pharmaceuticals, Gilead Sciences, Pfizer, etc] Global Scleroderma Drug Market Size, Share, Revenue, Sale- Updated Report 2021
Mar 04, 2021 (WiredRelease via Comtex) -- Let’s reset for growth beyond coronavirus with Market.Biz. Global Scleroderma Drug Market Research report contains...
marketresearch.biz · 2h ago
Global N-Acetylcysteine (Cas 616-91-1) Market 2021 - By Recent Size, Share, Business Strategy, Segmentation, Regional Demand, and In-Depth Insight of Sales, Revenue, Demand, and Growth Factors till 2026
Mar 03, 2021 (The Expresswire) -- Global N-Acetylcysteine (Cas 616-91-1) Market Comprehensive Analysis Report 2014-2026: Global “N-Acetylcysteine (Cas...
The Express Wire · 1d ago
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results
, /PRNewswire/ --(NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update after the market closes on . A conference call and live internet webcast will be held on , at to discuss the results.
PR Newswire - PRF · 1d ago
Global N-Acetylcysteine (Cas 616-91-1) Market Trends 2020 Industry Share, Growth, Business Challenges, Investment Opportunities, Demand, Key Manufacturers and 2025 Forecast Research Report
Mar 01, 2021 (The Expresswire) -- Global “N-Acetylcysteine (Cas 616-91-1) Market” research report 2021-2025 is a specialized and in-depth study of the...
The Express Wire · 3d ago
Hepatorenal Syndrome Treatment Market : Key Facts, Dynamics, Segments and Forecast Predictions Presented
Japan, Japan, Wed, 24 Feb 2021 05:41:11 / Comserve Inc. / -- Hepatorenal Syndrome Treatment Market Size, Demand-sales, Suppliers By Key Applications Detailed...
Comserve · 02/24 10:42
Cumberland Pharmaceuticals Awarded U.S. Patent 10,925,860 'Compositions and methods of treating cardiac fibrosis with ifetroban'
The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt the...
Benzinga · 02/23 12:09
Choroidal Neovascularization Drug Market Industry Growth,Forecast, Analysis,Manufacturers, Regions, Types and Applications 2020-2027 By Ameco Research
pune, India, Sun, 21 Feb 2021 23:48:52 / Comserve Inc. / -- Choroidal Neovascularization Drug market is segmented by Type, and by Application. Players,...
Comserve · 02/22 04:51
Choroidal Neovascularization Drug Market Set to Witness Growth 2021, Emerging industries, Challenges and Threats Faced by Key Vendors, Development Trends, Share, Size, Demand and 2027 Forecast Research Report
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Choroidal Neovascularization...
The Express Wire · 02/18 05:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CPIX. Analyze the recent business situations of Cumberland through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CPIX stock price target is 8.50 with a high estimate of 8.50 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 4.08M
% Owned: 27.13%
Shares Outstanding: 15.04M
TypeInstitutionsShares
Increased
5
117.45K
New
5
185.38K
Decreased
9
457.36K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.99%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Chief Executive Officer/Director
A. Kazimi
Chief Financial Officer
Michael Bonner
Executive Vice President/Director
Martin Cearnal
Executive Vice President
Leo Pavliv
Chief Compliance Officer/Vice President
James Herman
Independent Director
Gordon Bernard
Independent Director
Joseph Galante
Independent Director
Jonathan Griggs
Independent Director
Joey Jacobs
Independent Director
James Jones
Independent Director
Kenneth Krogulski
Independent Director
Caroline Young
No Data
About CPIX
Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

Webull offers kinds of Cumberland Pharmaceuticals, Inc. stock information, including NASDAQ:CPIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPIX stock methods without spending real money on the virtual paper trading platform.